Analysis of the TCGA dataset revealed that CMM patients with higher mRNA levels of MTH1 (greater than twofold) exhibit a shorter disease-free survival (p = 0.053) (Supplementary Fig. S1a) and a significantly shorter overall survival (p < 0.001) (Fig. 1a), suggesting a role of MTH1 as a prognostic marker for CMM. The gene discussed is NUDT1; the disease is familial congenital mirror movements.